Kan Kishibe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kan Kishibe has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Miki Takahara
Department of Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
8 shared publications - Takumi Kumai
Department of Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
7 shared publications - Hidekiyo Yamaki
Department of Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
6 shared publications - Kenzo Ohara
Department of Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
6 shared publications - Michihisa Kono
Department of Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
6 shared publications - Risa Wakisaka
Department of Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
6 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 75 (12)
Tumor-associated antigen-reactive T cells and clinical outcomes in head and neck squamous cell carcinoma treated with pembrolizumab plus chemotherapy
- 24 August 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 75 (12)
Open AccessTumor-associated antigen-reactive T cells and clinical outcomes in head and neck squamous cell carcinoma treated with pembrolizumab plus chemotherapy
- 24 April 2026
- Published by Elsevier in Auris Nasus Larynx
- Vol. 53 (3) , 429-434
Distinct mechanisms of otitis media with effusion before/after treatment in nasopharyngeal carcinoma
- 24 April 2026
- Published by Elsevier in Auris Nasus Larynx
- Vol. 53 (3) , 429-434
Distinct mechanisms of otitis media with effusion before/after treatment in nasopharyngeal carcinoma
- 28 March 2026
- Published by Elsevier in Oral Oncology
- Vol. 176, 107954
Combined positive score using 28–8 predicts nivolumab efficacy in HNSCC
- 28 March 2026
- Published by Elsevier in Oral Oncology
- Vol. 176, 107954
Combined positive score using 28–8 predicts nivolumab efficacy in HNSCC
- Open Access
ROR1 as an Immunotherapeutic Target for Inducing Antitumor Helper T Cell Responses Against Head and Neck Squamous Cell Carcinoma
Background/Objectives: Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer, with limited responsiveness to immune checkpoint inhibitors (ICIs). Cancer vaccine therapy is a promising novel immunotherapeutic approach that stimulates tumor-specific T cells. Receptor tyrosine kinase-like orphan receptor 1 (ROR1), which is overexpressed in malignant tumors but minimally expressed in normal tissues, presents a promising target for immunotherapy. This study aimed to evaluate ROR1 as a target for helper T lymphocyte (HTL)-based peptide vaccine immunotherapy in HNSCC. Methods: ROR1 expression in HNSCC tissues was assessed by immunohistochemistry. A novel ROR1-derived epitope (ROR1403–417) was identified and used to generate ROR1-reactive HTLs. Functional assays measuring IFN-γ and granzyme B secretion, as well as direct cytotoxicity, were performed. The effects of ICIs on HTL activity were also examined. The presence of ROR1-reactive T cells in the peripheral blood of patients with HNSCC was evaluated. Results: ROR1 positivity rates in HNSCC tissues were significantly higher (80.0%) than those in healthy controls (16.7%), and high ROR1 expression correlated with advanced clinical stages. HTL lines recognized the ROR1403–417 peptide in a human leukocyte antigen (HLA)-DR-restricted manner, secreted effector cytokines, and exhibited direct cytotoxicity against ROR1+ tumor cells. Dual PD-L1/PD-L2 blockade further enhanced HTL responses. ROR1-reactive T cells were detected in the peripheral blood of patients with HNSCC. Conclusions: ROR1 represents a promising target for immunotherapy in HNSCC. The ROR1403–417 peptide can elicit ROR1-reactive HTLs that exhibit antitumor responses against HNSCC cell lines, which can be enhanced by ICIs. These findings support the potential of ROR1-targeted peptide vaccine therapy for HNSCC.
Open AccessROR1 as an Immunotherapeutic Target for Inducing Antitumor Helper T Cell Responses Against Head and Neck Squamous Cell Carcinoma
Background/Objectives: Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer, with limited responsiveness to immune checkpoint inhibitors (ICIs). Cancer vaccine therapy is a promising novel immunotherapeutic approach that stimulates tumor-specific T cells. Receptor tyrosine kinase-like orphan receptor 1 (ROR1), which is overexpressed in malignant tumors but minimally expressed in normal tissues, presents a promising target for immunotherapy. This study aimed to evaluate ROR1 as a target for helper T lymphocyte (HTL)-based peptide vaccine immunotherapy in HNSCC. Methods: ROR1 expression in HNSCC tissues was assessed by immunohistochemistry. A novel ROR1-derived epitope (ROR1403–417) was identified and used to generate ROR1-reactive HTLs. Functional assays measuring IFN-γ and granzyme B secretion, as well as direct cytotoxicity, were performed. The effects of ICIs on HTL activity were also examined. The presence of ROR1-reactive T cells in the peripheral blood of patients with HNSCC was evaluated. Results: ROR1 positivity rates in HNSCC tissues were significantly higher (80.0%) than those in healthy controls (16.7%), and high ROR1 expression correlated with advanced clinical stages. HTL lines recognized the ROR1403–417 peptide in a human leukocyte antigen (HLA)-DR-restricted manner, secreted effector cytokines, and exhibited direct cytotoxicity against ROR1+ tumor cells. Dual PD-L1/PD-L2 blockade further enhanced HTL responses. ROR1-reactive T cells were detected in the peripheral blood of patients with HNSCC. Conclusions: ROR1 represents a promising target for immunotherapy in HNSCC. The ROR1403–417 peptide can elicit ROR1-reactive HTLs that exhibit antitumor responses against HNSCC cell lines, which can be enhanced by ICIs. These findings support the potential of ROR1-targeted peptide vaccine therapy for HNSCC.
- Open Access
Hypoxia-Targeted Immunotherapy with PD-1 Blockade in Head and Neck Cancer
Intratumoral hypoxia is associated with tumor progression, aggressiveness, and therapeutic resistance in several cancers. Hypoxia causes cancer cells to experience replication stress, thereby activating DNA damage and repair pathways. MutT homologue-1 (MTH1, also known as NUDT1), a member of the Nudix family, maintains the genomic integrity and viability of tumor cells in the hypoxic tumor microenvironment. Although hypoxia is associated with poor prognosis and can cause therapeutic resistance by regulating the microenvironment, it has not been considered a treatable target in cancer. This study aimed to investigate whether hypoxia-induced MTH1 is a useful target for immunotherapy and whether hypoxic conditions influence the antitumor activity of immune cells. Our results showed that MTH1 expression was elevated under hypoxic conditions in head and neck cancer cell lines. Furthermore, we identified a novel MTH1-targeting epitope peptide that can activate peptide-specific CD4+ helper T cells with cytotoxic activity. The proliferation and cytotoxic activity of T cells were maintained under hypoxic conditions, and PD-1 blockade further augmented the cytotoxicity. These results indicate that MTH1-targeted immunotherapy combined with checkpoint blockade can be an effective strategy for the treatment of hypoxic tumors.
Open AccessHypoxia-Targeted Immunotherapy with PD-1 Blockade in Head and Neck Cancer
Intratumoral hypoxia is associated with tumor progression, aggressiveness, and therapeutic resistance in several cancers. Hypoxia causes cancer cells to experience replication stress, thereby activating DNA damage and repair pathways. MutT homologue-1 (MTH1, also known as NUDT1), a member of the Nudix family, maintains the genomic integrity and viability of tumor cells in the hypoxic tumor microenvironment. Although hypoxia is associated with poor prognosis and can cause therapeutic resistance by regulating the microenvironment, it has not been considered a treatable target in cancer. This study aimed to investigate whether hypoxia-induced MTH1 is a useful target for immunotherapy and whether hypoxic conditions influence the antitumor activity of immune cells. Our results showed that MTH1 expression was elevated under hypoxic conditions in head and neck cancer cell lines. Furthermore, we identified a novel MTH1-targeting epitope peptide that can activate peptide-specific CD4+ helper T cells with cytotoxic activity. The proliferation and cytotoxic activity of T cells were maintained under hypoxic conditions, and PD-1 blockade further augmented the cytotoxicity. These results indicate that MTH1-targeted immunotherapy combined with checkpoint blockade can be an effective strategy for the treatment of hypoxic tumors.
- 12 May 2023
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 72 (8) , 2799-2812
Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer
Brachyury is a transcription factor belonging to the T-box gene family and is involved in the posterior formation of the mesoderm and differentiation of chordates. As the overexpression of Brachyury is a poor prognostic factor in a variety of cancers, the establishment of Brachyury-targeted therapy would be beneficial for the treatment of aggressive tumors. Because transcription factors are difficult to treat with a therapeutic antibody, peptide vaccines are a feasible approach for targeting Brachyury. In this study, we identified Brachyury-derived epitopes that elicit antigen-specific and tumor-reactive CD4+ T cells that directly kill tumors. T cells recognizing Brachyury epitopes were present in patients with head and neck squamous cell carcinoma. Next, we focused on gemcitabine (GEM) as an immunoadjuvant to augment the efficacy of antitumor responses by T cells. Interestingly, GEM upregulated HLA class I and HLA-DR expression in tumor, followed by the upregulation of anti-tumor T cell responses. As tumoral PD-L1 expression was also augmented by GEM, PD-1/PD-L1 blockade and GEM synergistically enhanced the tumor-reactivity of Brachyury-reactive T cells. The synergy between the PD-1/PD-L1 blockade and GEM was also confirmed in a mouse model of head and neck squamous cell carcinoma. These results suggest that the combined treatment of Brachyury peptide with GEM and immune checkpoint blockade could be a promising immunotherapy against head and neck cancer.
- 12 May 2023
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 72 (8) , 2799-2812
Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer
Brachyury is a transcription factor belonging to the T-box gene family and is involved in the posterior formation of the mesoderm and differentiation of chordates. As the overexpression of Brachyury is a poor prognostic factor in a variety of cancers, the establishment of Brachyury-targeted therapy would be beneficial for the treatment of aggressive tumors. Because transcription factors are difficult to treat with a therapeutic antibody, peptide vaccines are a feasible approach for targeting Brachyury. In this study, we identified Brachyury-derived epitopes that elicit antigen-specific and tumor-reactive CD4+ T cells that directly kill tumors. T cells recognizing Brachyury epitopes were present in patients with head and neck squamous cell carcinoma. Next, we focused on gemcitabine (GEM) as an immunoadjuvant to augment the efficacy of antitumor responses by T cells. Interestingly, GEM upregulated HLA class I and HLA-DR expression in tumor, followed by the upregulation of anti-tumor T cell responses. As tumoral PD-L1 expression was also augmented by GEM, PD-1/PD-L1 blockade and GEM synergistically enhanced the tumor-reactivity of Brachyury-reactive T cells. The synergy between the PD-1/PD-L1 blockade and GEM was also confirmed in a mouse model of head and neck squamous cell carcinoma. These results suggest that the combined treatment of Brachyury peptide with GEM and immune checkpoint blockade could be a promising immunotherapy against head and neck cancer.
- Open Access
- 25 June 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (7) , 1381
Extranodal NK/T-Cell Lymphoma, Nasal Type: Genetic, Biologic, and Clinical Aspects with a Central Focus on Epstein–Barr Virus Relation
Extranodal NK/T-Cell Lymphoma, nasal type (ENKTL-NT) has some salient aspects. The lymphoma is commonly seen in Eastern Asia, has progressive necrotic lesions in the nasal cavity, makes midfacial destructive lesions, and shows poor prognosis. The lymphoma cell is originated from either NK- or γδ T-cells, which express CD56. Since the authors first demonstrated the existence of Epstein–Barr virus (EBV) DNA and EBV oncogenic proteins in lymphoma cells, ENKTL-NT has been recognized as an EBV-associated malignancy. Because the angiocentric and polymorphous lymphoma cells are mixed with inflammatory cells on a necrotic background, the diagnosis of ENKTL-NT requires CD56 immunostaining and EBER in situ hybridization. In addition, serum the EBV DNA level is useful for the diagnosis and monitoring of ENKTL-NT. Although ENKTL-NT is refractory lymphoma, the prognosis is improved by the development of therapies such as concomitant chemoradiotherapy. The basic research reveals that a wide variety of intracellular/cell surface molecules, cytokines, chemokines, and micro RNAs are involved in lymphomagenesis, and some of them are related to EBV. Understanding lymphoma behavior introduces new therapeutic strategies, such as the usage of immune checkpoint inhibitors, peptide vaccines, and molecular targeting therapy. This review addresses recent advances in basic and clinical aspects of ENKTL-NT, especially its relation to EBV features.
- 25 June 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (7) , 1381
Open AccessExtranodal NK/T-Cell Lymphoma, Nasal Type: Genetic, Biologic, and Clinical Aspects with a Central Focus on Epstein–Barr Virus Relation
Extranodal NK/T-Cell Lymphoma, nasal type (ENKTL-NT) has some salient aspects. The lymphoma is commonly seen in Eastern Asia, has progressive necrotic lesions in the nasal cavity, makes midfacial destructive lesions, and shows poor prognosis. The lymphoma cell is originated from either NK- or γδ T-cells, which express CD56. Since the authors first demonstrated the existence of Epstein–Barr virus (EBV) DNA and EBV oncogenic proteins in lymphoma cells, ENKTL-NT has been recognized as an EBV-associated malignancy. Because the angiocentric and polymorphous lymphoma cells are mixed with inflammatory cells on a necrotic background, the diagnosis of ENKTL-NT requires CD56 immunostaining and EBER in situ hybridization. In addition, serum the EBV DNA level is useful for the diagnosis and monitoring of ENKTL-NT. Although ENKTL-NT is refractory lymphoma, the prognosis is improved by the development of therapies such as concomitant chemoradiotherapy. The basic research reveals that a wide variety of intracellular/cell surface molecules, cytokines, chemokines, and micro RNAs are involved in lymphomagenesis, and some of them are related to EBV. Understanding lymphoma behavior introduces new therapeutic strategies, such as the usage of immune checkpoint inhibitors, peptide vaccines, and molecular targeting therapy. This review addresses recent advances in basic and clinical aspects of ENKTL-NT, especially its relation to EBV features.
- 1 April 2017
- Published by Elsevier in Human Immunology
- Vol. 78 (4) , 375-383
Up-regulation of CX3CR1 on tonsillar CD8-positive cells in patients with IgA nephropathy
- 1 April 2017
- Published by Elsevier in Human Immunology
- Vol. 78 (4) , 375-383
Up-regulation of CX3CR1 on tonsillar CD8-positive cells in patients with IgA nephropathy
- Open Access
- 20 August 2013
- Published by Wiley in American Journal of Hematology
- Vol. 89 (1) , 25-33
Downregulation of miR‐15a due to LMP1 promotes cell proliferation and predicts poor prognosis in nasal NK/T‐cell lymphoma
Nasal NK/T‐cell lymphoma (NNKTL) is an Epstein‐Barr virus (EBV)‐associated malignancy and has distinct clinical and histological features. However, its genetic features are hitherto unclear. MicroRNAs (miRNAs) play a crucial role in the pathogenesis of several malignancies via regulating gene expression. In this study, we investigated whether the specific microRNAs were related to the tumor behaviors in NNKTL. MiRNA array and Quantitative RT‐PCR analyses revealed that miR‐15a was expressed at a much lower level in NNKTL cells (SNK‐1, SNK‐6, and SNT‐8) than in normal peripheral NK cells and EBV‐negative NK cell line KHYG‐1. Quantitative PCR and western blot analyses showed that the expression of MYB and cyclin D1, which are validated targets of miR‐15a, was higher in NNKTL cells. Transfection of NNKTL cells (SNK‐6 and SNT‐8) with a miR‐15a precursor decreased MYB and cyclin D1 levels, thereby blocking G1/S transition and cell proliferation. Knockdown of EBV‐encoded latent membrane protein 1 (LMP1) significantly increased miR‐15a expression in SNK‐6 cells. In NNKTL tissues, we found that reduced miR‐15a expression, which correlated with MYB and cyclin D1 expression, was associated with poor prognosis of NNKTL patients. These data suggest that downregulation of miR‐15a, possibly due to LMP1, implicates in the pathogenesis of NNKTL by inducing cell proliferation via MYB and cyclin D1. Thus, miR‐15a could be a potential target for antitumor therapy and a prognostic predictor for NNKTL. Am. J. Hematol. 89:25–33, 2014.
- 20 August 2013
- Published by Wiley in American Journal of Hematology
- Vol. 89 (1) , 25-33
Open AccessDownregulation of miR‐15a due to LMP1 promotes cell proliferation and predicts poor prognosis in nasal NK/T‐cell lymphoma
Nasal NK/T‐cell lymphoma (NNKTL) is an Epstein‐Barr virus (EBV)‐associated malignancy and has distinct clinical and histological features. However, its genetic features are hitherto unclear. MicroRNAs (miRNAs) play a crucial role in the pathogenesis of several malignancies via regulating gene expression. In this study, we investigated whether the specific microRNAs were related to the tumor behaviors in NNKTL. MiRNA array and Quantitative RT‐PCR analyses revealed that miR‐15a was expressed at a much lower level in NNKTL cells (SNK‐1, SNK‐6, and SNT‐8) than in normal peripheral NK cells and EBV‐negative NK cell line KHYG‐1. Quantitative PCR and western blot analyses showed that the expression of MYB and cyclin D1, which are validated targets of miR‐15a, was higher in NNKTL cells. Transfection of NNKTL cells (SNK‐6 and SNT‐8) with a miR‐15a precursor decreased MYB and cyclin D1 levels, thereby blocking G1/S transition and cell proliferation. Knockdown of EBV‐encoded latent membrane protein 1 (LMP1) significantly increased miR‐15a expression in SNK‐6 cells. In NNKTL tissues, we found that reduced miR‐15a expression, which correlated with MYB and cyclin D1 expression, was associated with poor prognosis of NNKTL patients. These data suggest that downregulation of miR‐15a, possibly due to LMP1, implicates in the pathogenesis of NNKTL by inducing cell proliferation via MYB and cyclin D1. Thus, miR‐15a could be a potential target for antitumor therapy and a prognostic predictor for NNKTL. Am. J. Hematol. 89:25–33, 2014.
- Open Access
- 4 December 2012
- Published by Wiley in British Journal of Haematology
- Vol. 160 (3) , 331-342
Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27
Summary: Nasal natural killer (NK)/T cell lymphoma (NNKTL) is associated with Epstein–Barr virus (EBV). The present study analysed gene expression patterns of the NNKTL cell lines SNK6, SNK1 and SNT8, which are positive for EBV and latent membrane protein (LMP)‐1, using a complementary DNA array analysis. We found that CD70 was specifically expressed in SNK6 and SNT8. Reverse transcription polymerase chain reaction and flow cytometric analyses confirmed that CD70 was expressed in all 3 NNKTL cell lines, but not in the other EBV‐positive NK‐cell lines. In vitro studies showed that NNKTL cell lines proliferated, in a dose‐dependent fashion, in response to exogenous soluble CD27, which is the ligand for CD70. In NNKTL patients, we confirmed that the CD70 was expressed on the lymphoma cells in NNKTL tissues and that soluble CD27 was present in sera at higher levels as compared to healthy individuals. Finally, complement‐dependent cytotoxicity assay showed that anti‐CD70 antibody mediated effective complement‐dependent killing of NNKTL cells and the affected target CD70 expression on the cells. These results suggest that CD70 acts as a functional receptor binding to soluble CD27, resulting in lymphoma progression and that immunotherapy using anti‐CD70 antibody may be a potential candidate for treatment for NNKTL.
- 4 December 2012
- Published by Wiley in British Journal of Haematology
- Vol. 160 (3) , 331-342
Open AccessExpression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27
Summary: Nasal natural killer (NK)/T cell lymphoma (NNKTL) is associated with Epstein–Barr virus (EBV). The present study analysed gene expression patterns of the NNKTL cell lines SNK6, SNK1 and SNT8, which are positive for EBV and latent membrane protein (LMP)‐1, using a complementary DNA array analysis. We found that CD70 was specifically expressed in SNK6 and SNT8. Reverse transcription polymerase chain reaction and flow cytometric analyses confirmed that CD70 was expressed in all 3 NNKTL cell lines, but not in the other EBV‐positive NK‐cell lines. In vitro studies showed that NNKTL cell lines proliferated, in a dose‐dependent fashion, in response to exogenous soluble CD27, which is the ligand for CD70. In NNKTL patients, we confirmed that the CD70 was expressed on the lymphoma cells in NNKTL tissues and that soluble CD27 was present in sera at higher levels as compared to healthy individuals. Finally, complement‐dependent cytotoxicity assay showed that anti‐CD70 antibody mediated effective complement‐dependent killing of NNKTL cells and the affected target CD70 expression on the cells. These results suggest that CD70 acts as a functional receptor binding to soluble CD27, resulting in lymphoma progression and that immunotherapy using anti‐CD70 antibody may be a potential candidate for treatment for NNKTL.